Annual Current Liabilities
$14.94 M
-$7.01 M-31.94%
December 31, 2023
Summary
- As of February 8, 2025, LVTX annual total current liabilities is $14.94 million, with the most recent change of -$7.01 million (-31.94%) on December 31, 2023.
- During the last 3 years, LVTX annual current liabilities has risen by +$7.61 million (+103.69%).
- LVTX annual current liabilities is now -31.94% below its all-time high of $21.95 million, reached on December 31, 2022.
Performance
LVTX Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$15.20 M
+$1.09 M+7.72%
September 30, 2024
Summary
- As of February 8, 2025, LVTX quarterly total current liabilities is $15.20 million, with the most recent change of +$1.09 million (+7.72%) on September 30, 2024.
- Over the past year, LVTX quarterly current liabilities has dropped by -$5.55 million (-26.76%).
- LVTX quarterly current liabilities is now -35.52% below its all-time high of $23.57 million, reached on March 31, 2023.
Performance
LVTX Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
LVTX Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -31.9% | -26.8% |
| 3 y3 years | +103.7% | -26.8% |
| 5 y5 years | +949.2% | -26.8% |
LVTX Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -31.9% | +32.8% | -35.5% | +35.1% |
| 5 y | 5-year | -31.9% | +949.2% | -35.5% | +107.2% |
| alltime | all time | -31.9% | +949.2% | -35.5% | +107.2% |
LAVA Therapeutics NV Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $15.20 M(+7.7%) |
| Jun 2024 | - | $14.11 M(+8.3%) |
| Mar 2024 | - | $13.03 M(-12.8%) |
| Dec 2023 | $14.94 M(-31.9%) | $14.94 M(-28.0%) |
| Sep 2023 | - | $20.75 M(-7.1%) |
| Jun 2023 | - | $22.33 M(-5.3%) |
| Mar 2023 | - | $23.57 M(+7.4%) |
| Dec 2022 | $21.95 M | $21.95 M(+22.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $17.86 M(+6.8%) |
| Jun 2022 | - | $16.73 M(+2.4%) |
| Mar 2022 | - | $16.34 M(+45.3%) |
| Dec 2021 | $11.25 M(+53.3%) | $11.25 M(-13.4%) |
| Sep 2021 | - | $12.99 M(-5.2%) |
| Jun 2021 | - | $13.71 M(-27.3%) |
| Mar 2021 | - | $18.86 M(+157.1%) |
| Dec 2020 | $7.33 M(+415.1%) | $7.33 M |
| Dec 2019 | $1.42 M | - |
FAQ
- What is LAVA Therapeutics NV annual total current liabilities?
- What is the all time high annual current liabilities for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV annual current liabilities year-on-year change?
- What is LAVA Therapeutics NV quarterly total current liabilities?
- What is the all time high quarterly current liabilities for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV quarterly current liabilities year-on-year change?
What is LAVA Therapeutics NV annual total current liabilities?
The current annual current liabilities of LVTX is $14.94 M
What is the all time high annual current liabilities for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high annual total current liabilities is $21.95 M
What is LAVA Therapeutics NV annual current liabilities year-on-year change?
Over the past year, LVTX annual total current liabilities has changed by -$7.01 M (-31.94%)
What is LAVA Therapeutics NV quarterly total current liabilities?
The current quarterly current liabilities of LVTX is $15.20 M
What is the all time high quarterly current liabilities for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high quarterly total current liabilities is $23.57 M
What is LAVA Therapeutics NV quarterly current liabilities year-on-year change?
Over the past year, LVTX quarterly total current liabilities has changed by -$5.55 M (-26.76%)